Search

Author/Creator Bodla, Shankar

1. Hyperglycemia and Phosphatidylinositol 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin (PI3K/AKT/mTOR) Inhibitors in Phase I Trials: Incidence, Predictive Factors, and Management. (5th May 2016)

Authors:
Khan, Khurum H.; Wong, Mabel; Rihawi, Karim; Bodla, Shankar; Morganstein, Daniel; Banerji, Udai; Molife, Lulama R.
Journal:
Oncologist
Issue:
Volume 21:Number 7(2016)
Page Start:
855
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Hyperglycemia and Phosphatidylinositol 3‐Kinase/Protein Kinase B/Mammalian Target of Rapamycin (PI3K/AKT/mTOR) Inhibitors in Phase I Trials: Incidence, Predictive Factors, and Management. (5th May 2016)

Authors:
Khan, Khurum H.; Wong, Mabel; Rihawi, Karim; Bodla, Shankar; Morganstein, Daniel; Banerji, Udai; Molife, Lulama R.
Journal:
Oncologist
Issue:
Volume 21:Number 7(2016)
Page Start:
855
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Phase I clinical trials in patients with advanced non-small cell lung cancer treated within a Drug Development Unit: What have we learnt?. (September 2017)

Authors:
Capelan, Marta; Roda, Desamparados; Geuna, Elena; Rihawi, Karim; Bodla, Shankar; Kaye, Stan B.; Bhosle, Jaishree; Banerji, Udai; O'Brien, Mary; de Bono, Johann S.; Popat, Sanjay; Yap, Timothy A.
Journal:
Lung cancer
Issue:
Volume 111(2017)
Page Start:
6
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search